Want to see AU:WNX full AI Analyst Report?
Top Page
Wellnex Life Ltd
(Sydney:WNX)
Select Model
Select Model
Rating:41Neutral
Price Target:
AU$0.05
▼(-41.11% Downside)
Action:Reiterated
Date:07/02/26
The score is primarily constrained by weak financial performance—ongoing losses and negative operating/free cash flow are the largest risks, despite moderate leverage on the balance sheet. Technicals also weigh on the outlook, with the price below key longer-term moving averages and negative MACD indicating a sustained downtrend. Valuation provides limited offset because the negative P/E reflects losses and dividend yield data is unavailable.
Positive Factors
Manageable leverage / balance sheet stability
A moderate debt-to-equity ratio of 0.48 indicates manageable leverage and less immediate refinancing risk. This structural cushion supports near-term operations and gives the company flexibility to fund working capital or invest in growth without excessive interest burden over the next 2-6 months.
Negative Factors
Negative operating & free cash flow
Persistent negative operating and free cash flows reduce internal funding for inventory, marketing, and R&D and force reliance on external capital. Over several months this constrains growth execution, increases liquidity risk, and can raise financing costs or dilute shareholders if new capital is needed.
Read all positive and negative factors
Positive Factors
Negative Factors
Manageable leverage / balance sheet stability
A moderate debt-to-equity ratio of 0.48 indicates manageable leverage and less immediate refinancing risk. This structural cushion supports near-term operations and gives the company flexibility to fund working capital or invest in growth without excessive interest burden over the next 2-6 months.
Read all positive factors
Wellnex Life Ltd (WNX) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$4.02M
Dividend YieldN/A
Average Volume (3M)51.95K
Price to Earnings (P/E)―
Beta (1Y)1.16
Revenue Growth5.79%
EPS Growth29.75%
CountryAU
Employees3
SectorConsumer Defensive
Sector Strength42
IndustryFood Distribution
Share Statistics
EPS (TTM)-0.28
Shares Outstanding73,026,810
10 Day Avg. Volume31,968
30 Day Avg. Volume51,946
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.69
Price to Sales (P/S)0.33
P/FCF Ratio-11.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.05
Revenue Forecast (FY)AU$48.60M
Wellnex Life Ltd Business Overview & Revenue Model
Company Description
Wellnex Life Limited, together with its subsidiaries, develops, markets, and sells health and wellness products in Australia, New Zealand, and the United Kingdom. The company offers topical anti-inflammatory creams, sprays, and roll-ons under the ...
How the Company Makes Money
Wellnex Life Ltd generates revenue primarily from selling its health and wellness products. Key revenue streams include (1) wholesale and distributor sales to retailers and other channel partners (i.e., selling finished goods in bulk at a margin o...
Wellnex Life Ltd Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
40
Negative
Cash Flow
30
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 24.58M | 23.63M | 16.93M | 27.89M | 18.61M | 1.20M |
| Gross Profit | 5.92M | 6.88M | -776.00K | 4.75M | 4.50M | -165.00K |
| EBITDA | -4.46M | -6.62M | -10.57M | -6.82M | -6.35M | -18.41M |
| Net Income | -9.87M | -15.60M | -13.74M | -13.85M | -7.45M | -24.69M |
Balance Sheet | ||||||
| Total Assets | 27.83M | 27.84M | 30.92M | 15.04M | 19.61M | 10.42M |
| Cash, Cash Equivalents and Short-Term Investments | 975.00K | 497.00K | 903.00K | 322.00K | 3.18M | 7.78M |
| Total Debt | 10.03M | 5.45M | 10.67M | 6.95M | 7.86M | 9.31M |
| Total Liabilities | 17.78M | 16.59M | 24.86M | 14.45M | 15.25M | 10.67M |
| Stockholders Equity | 10.04M | 11.25M | 6.06M | 594.00K | 4.36M | -249.00K |
Cash Flow | ||||||
| Free Cash Flow | -1.41M | -666.00K | -6.82M | -6.19M | -8.65M | -5.17M |
| Operating Cash Flow | -1.41M | -666.00K | -6.82M | -6.19M | -8.61M | -4.38M |
| Investing Cash Flow | -8.07M | -8.29M | -13.42M | -2.20M | -3.65M | 9.45M |
| Financing Cash Flow | 10.18M | 8.55M | 20.82M | 5.53M | 7.66M | 1.55M |
Wellnex Life Ltd Technical Analysis
Neutral
0.09
Price Trends
0.06
Negative
0.07
Negative
0.12
Negative
Market Momentum
<0.01
Negative
56.63
Neutral
16.90
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:WNX, the sentiment is Neutral. The current price of 0.09 is above the 20-day moving average (MA) of 0.05, above the 50-day MA of 0.06, and below the 200-day MA of 0.12, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 56.63 is Neutral, neither overbought nor oversold. The STOCH value of 16.90 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:WNX.
Wellnex Life Ltd Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
56 Neutral | AU$71.53M | 19.05 | 8.70% | ― | 23.29% | ― | |
44 Neutral | AU$29.43M | -30.77 | -321.20% | ― | 2.96% | -866.67% | |
44 Neutral | AU$7.33M | -0.01 | 226.76% | ― | -32.83% | 83.37% | |
41 Neutral | AU$4.02M | -0.20 | -92.72% | ― | 5.79% | 29.75% | |
40 Underperform | AU$13.33M | -2.78 | -41.69% | ― | 53.69% | 45.24% |
* Consumer Defensive Sector Average
AU:WNX
Wellnex Life Ltd
0.06
-0.19
-77.55%
AU:BUB
Bubs Australia Ltd.
0.08
-0.10
-55.56%
AU:NUC
Nuchev Pty Ltd
0.09
-0.07
-45.16%
AU:HCT
Holista Colltech Limited
0.08
0.01
15.94%
AU:NGS
Nutritional Growth Solutions Ltd.
0.02
0.00
0.00%
Wellnex Life Ltd Corporate Events
Wellnex Life Extends Director Loan Repayment and Re-engages Former CEO as Consultant
Apr 22, 2026
Wellnex Life Limited has renegotiated the repayment terms of loans totaling about $2.88 million owed to former directors, pushing the due date from 20 April 2026 to no later than 21 July 2026 in exchange for an additional $150,000 added to princip...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.